Ivorra Cano, Antoni, 1974-Sánchez Velázquez, Patricia, 1985-Castellví Fernández, QuimVillanueva, AlbertoIglesias Coma, MarQuesada Diez, RitaPañella Vilamú, Clara, 1987-Cáceres Aguilar, MarioDorcaratto, DimitriAndaluz, AnnaMoll, XavierBurdío, José M.Grande Posa, LuísBurdío Pinilla, Fernando2017-05-162017-05-162017Sánchez-Velázquez P, Cstellví Q, Villanueva A, Iglesias M, Quesada R, Pañella C, Cáceres M, Dorcaratto D, Andaluz A, Moll X, Burdío JM, Grande L, Ivorra A, Burdío F. Long-term effectiveness of irreversible electroporation in a murine model of colorectal liver metastasis. Sci Rep. 2017;7:44821. DOI: 10.1038/srep448212045-2322http://hdl.handle.net/10230/32129Irreversible electroporation (IRE) has recently gained in popularity as an ablative technique, however little is known about its oncological long-term outcomes. To determine the long-time survival of animals treated with a high dose of IRE and which histological changes it induces in tumoral tissue, IRE ablation was performed in forty-six athymic-nude mice with KM12C tumors implanted in the liver by applying electric current with different voltages (2000 V/cm, 1000 V/cm). The tumors were allowed to continue to grow until the animals reached the end-point criteria. Histology was harvested and the extent of tumor necrosis was semi-quantitatively assessed. IRE treatment with the 2000 V/cm protocol significantly prolonged median mouse survival from 74.3 ± 6.9 days in the sham group to 112.5 ± 15.2 days in the 2000 V/cm group. No differences were observed between the mean survival of the 1000 V/cm and the sham group (83.2 ± 16.4 days, p = 0.62). Histology revealed 63.05% ± 23.12 of tumor necrosis in animals of the 2000 V/cm group as compared to 17.50% ± 2.50 in the 1000 V/cm group and 25.6% ± 22.1 in the Sham group (p = 0.001). IRE prolonged the survival of animals treated with the highest electric field (2000 V/cm). The animals in this group showed significantly higher rate of tumoral necrosis.application/pdfengThis work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ © The Author(s) 2017info:eu-repo/semantics/articlehttp://dx.doi.org/10.1038/srep44821Cancer modelsSurgical oncologyinfo:eu-repo/semantics/openAccess